Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 115,900 shares, a growth of 94.5% from the February 28th total of 59,600 shares. Currently, 2.3% of the shares of the company are sold short. Based on an average trading volume of 1,850,000 shares, the days-to-cover ratio is presently 0.1 days.
Kazia Therapeutics Price Performance
NASDAQ:KZIA traded down $0.07 during trading hours on Friday, reaching $0.88. The company’s stock had a trading volume of 69,902 shares, compared to its average volume of 852,788. The firm has a 50-day simple moving average of $1.09 and a 200-day simple moving average of $3.00. Kazia Therapeutics has a 1 year low of $0.76 and a 1 year high of $15.80.
Analyst Ratings Changes
Separately, Maxim Group began coverage on Kazia Therapeutics in a research note on Thursday, February 6th. They issued a “buy” rating and a $3.00 target price for the company.
Institutional Investors Weigh In On Kazia Therapeutics
A hedge fund recently bought a new stake in Kazia Therapeutics stock. Barclays PLC acquired a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned 2.38% of Kazia Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 30.89% of the company’s stock.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.
Recommended Stories
- Five stocks we like better than Kazia Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- Where Do I Find 52-Week Highs and Lows?
- MarketBeat Week in Review – 03/24 – 03/28
- What is a Stock Market Index and How Do You Use Them?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
